Fisher Asset Management LLC Has $36.74 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Fisher Asset Management LLC lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 119,865 shares of the company’s stock after selling 3,241 shares during the quarter. Fisher Asset Management LLC’s holdings in Medpace were worth $36,742,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Medpace by 2.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock worth $2,114,000 after purchasing an additional 148 shares during the last quarter. Portside Wealth Group LLC boosted its stake in shares of Medpace by 14.8% during the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after buying an additional 183 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Medpace by 355.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock valued at $1,090,000 after acquiring an additional 2,774 shares in the last quarter. Norden Group LLC increased its position in shares of Medpace by 207.8% in the fourth quarter. Norden Group LLC now owns 5,014 shares of the company’s stock valued at $1,537,000 after acquiring an additional 3,385 shares during the last quarter. Finally, Retirement Systems of Alabama increased its position in shares of Medpace by 0.3% in the fourth quarter. Retirement Systems of Alabama now owns 62,106 shares of the company’s stock valued at $19,037,000 after acquiring an additional 204 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on MEDP shares. UBS Group upgraded Medpace from a “neutral” rating to a “buy” rating and raised their price target for the company from $282.00 to $452.00 in a research note on Thursday, February 15th. Guggenheim raised their target price on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 price target on the stock. Robert W. Baird lifted their price objective on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their target price for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Medpace presently has an average rating of “Moderate Buy” and a consensus target price of $443.00.

Medpace Stock Performance

Shares of MEDP stock opened at $392.57 on Friday. Medpace Holdings, Inc. has a 52 week low of $197.39 and a 52 week high of $421.00. The company has a market capitalization of $12.16 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 1.95 and a beta of 1.40. The company has a 50-day simple moving average of $398.08 and a 200 day simple moving average of $331.07.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million during the quarter, compared to the consensus estimate of $512.39 million. During the same period last year, the business posted $2.27 earnings per share. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. Sell-side analysts forecast that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Insider Activity at Medpace

In other Medpace news, VP Susan E. Burwig sold 102 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now owns 15,181 shares in the company, valued at approximately $6,117,943. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares in the company, valued at $2,170,274,237.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The disclosure for this sale can be found here. Insiders sold 204,442 shares of company stock worth $82,702,867 in the last ninety days. 20.30% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.